EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Peri-Implant Mucositis Treatment with a Chlorexidine Gel with A.D.S. 0.5%, PVP-VA and Sodium DNA vs a Placebo Gel: A Randomized Controlled Pilot Clinical Trial

Felice Lorusso, Gianluca Tartaglia, Francesco Inchingolo, Antonio Scarano

Frontiers in Bioscience-Elite · 31.10.2022 · 14 (4)

DOI: 10.31083/j.fbe1404030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Bioscience-Elite, online erschienen am 31.10.2022. Verfasst von Felice Lorusso und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy. Hauptthemen laut MEDLINE: Mucositis, Peri-Implantitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peri-implant mucositis is a bacterial and inflammatory disease of implant surrounding soft tissues. Chlorhexidine (CHX) associated with PVP-VA (Polyvinylpyrrolidone/vinyl acetate) has an adjuvant function in the antibacterial activity: it protects the film-forming layer, due to polymer, from microbial contamination or over-infection, and prolongs its permanence, without a direct action on the tissues and wounds. Sodium DNA is able to improve gingival trophism. The aim of the study was to compare a gel with CHX and antidiscoloration system (A.D.S.) 0.5% with the addition of PVP-VA and sodium DNA with a placebo gel without chlorexidine in peri-implant mucositis treatment.

Methods

Trial design: A single center randomized controlled pilot clinical trial was conducted on a total of 24 patients with mucositis, randomly allocated into two groups. In the group (A) (n = 12) patients were treated with a gel with CHX + A.D.S. 0.5% while a placebo gel was used in the group (B) (n = 12). Outcome: Plaque Index (PI) (primary outcome), Bleeding on probing (BOP) and Gingival Index (GI) (secondary outcomes) were assessed at baseline and at 2 weeks after treatment period.

Results

Mean PI score recorded at baseline was 2.4 ± 0.4 [95% CI: –2.682/7.482] in the group (A) and 2.2 ± 0.5 [95% CI: –4.153/8.553] in the group (B) (p > 0.05) while mean PI score at 2 weeks was 0.5 ± 0.4 [95% CI: –4.582/5.582] and 1.7 ± 1.9 [95% CI: –9.736/13.14] in the group and in the group respectively (p < 0.05). Mean BOP value at baseline was 57.1 ± 15.2% [95% CI: –136.0/250.2] in the group (A) and 55.3% ± 11.7% [95% CI: –93.36/204.0] (p > 0.05) while mean BOP value at 2 weeks follow-up was 14.3% ± 6.6% [95% CI: –69.56/98.16] (A) and 45.4% ± 9.8% [95% CI: –79.12/169.9] (B) respectively (p < 0.05).

Conclusions

A significant reduction in gingival inflammation indexes was found at 2 weeks in patients with peri-implant mucositis treated with a gel with CHX + A.D.S. 0.5% with the addition of PVP-VA and sodium DNA compared to those treated with a placebo gel. Clinical Trial Registration: 2019-004976-20.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucositisPeri-ImplantitisHumansChlorhexidineDNAPyrrolidinesVinyl Compounds

Stichwörter der Autor:innen

bacterial biofilmsdental implantsmucositisoral hygieneperi-implant diseaseplaque

Substanzen

ChlorhexidineDNApoly(vinylpyrrolidone-co-vinyl-acetate)PyrrolidinesVinyl Compounds

Autor:innen und Institutionen

  • Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milan, Italy.
  • Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.
  • Department of Oral Implantology, Dental Research Division, College Ingà, UNINGÁ, 29312 Cachoeiro de Itapemirim, Espirito Santo, Brazil.

Zitieren

APA

Lorusso, F., Tartaglia, G., Inchingolo, F., & Scarano, A. (2022). Peri-Implant Mucositis Treatment with a Chlorexidine Gel with A.D.S. 0.5%, PVP-VA and Sodium DNA vs a Placebo Gel: A Randomized Controlled Pilot Clinical Trial. Frontiers in Bioscience-Elite, 14(4). https://doi.org/10.31083/j.fbe1404030

Vancouver

Lorusso F, Tartaglia G, Inchingolo F, Scarano A. Peri-Implant Mucositis Treatment with a Chlorexidine Gel with A.D.S. 0.5%, PVP-VA and Sodium DNA vs a Placebo Gel: A Randomized Controlled Pilot Clinical Trial. Frontiers in Bioscience-Elite. 2022;14(4). doi:10.31083/j.fbe1404030

BibTeX
@article{Lorusso2022,
  author = {Lorusso, Felice and Tartaglia, Gianluca and Inchingolo, Francesco and Scarano, Antonio},
  title = {Peri-Implant Mucositis Treatment with a Chlorexidine Gel with A.D.S. 0.5%, PVP-VA and Sodium DNA vs a Placebo Gel: A Randomized Controlled Pilot Clinical Trial},
  journal = {Frontiers in Bioscience-Elite},
  year = {2022},
  volume = {14},
  number = {4},
  doi = {10.31083/j.fbe1404030}
}
Kostenlos starten →